Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.45 -0.7%	$1.30	$0.99 ▼ $5.17	$157.01M	0.42	1.19 million shs	750,839 shs
EPRX Eupraxia Pharmaceuticals	$3.93	$3.59	$2.20 ▼ $4.48	$140.89M	N/A	13,100 shs	7,576 shs
SLN Silence Therapeutics	$5.90 -0.7%	$3.62	$1.97 ▼ $22.47	$176.59M	1.2	302,428 shs	188,892 shs
VTL Vital Therapies	$0.66 -3.0%	$8.88	$0.15 ▼ $9.75	$27.96M	3.51	21.62 million shs	4.97 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	-0.68%	+15.08%	+5.07%	-27.14%	+43.56%
EPRX Eupraxia Pharmaceuticals	0.00%	+1.55%	-4.15%	-1.13%	+41.37%
SLN Silence Therapeutics	-0.67%	+16.60%	+59.46%	+31.11%	-72.61%
VTL Vital Therapies	-25.28%	-26.13%	-46.87%	-42.85%	-44.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.4546 of 5 stars	3.6	1.0	0.0	0.0	2.6	1.7	1.3
EPRX Eupraxia Pharmaceuticals	2.1707 of 5 stars	3.7	1.0	0.0	0.0	2.5	0.0	0.6
SLN Silence Therapeutics	3.7634 of 5 stars	4.4	4.0	0.0	0.0	3.7	1.7	0.6
VTL Vital Therapies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$9.71	569.95% Upside
EPRX Eupraxia Pharmaceuticals	3.33	Buy	$10.50	167.18% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	473.45% Upside
VTL Vital Therapies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VTL, SLN, EPRX, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00
5/9/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $35.00
3/18/2025	ACRS Aclaris Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight
3/7/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$15.00
3/7/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
3/5/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$49.00 ➝ $45.00
3/4/2025	ACRS Aclaris Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$17.78M	8.83	N/A	N/A	$2.22 per share	0.65
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
SLN Silence Therapeutics	$27.70M	6.37	N/A	N/A	$0.71 per share	8.31
VTL Vital Therapies	N/A	N/A	N/A	N/A	$0.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$88.48M	-$1.39	N/A	N/A	N/A	-136.65%	-40.26%	-31.71%	8/6/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$28.22M	-$0.76	N/A	N/A	N/A	N/A	-219.64%	-96.00%	8/6/2025 (Estimated)
SLN Silence Therapeutics	-$53.82M	-$1.50	N/A	N/A	N/A	-342.00%	-62.81%	-33.89%	N/A
VTL Vital Therapies	-$41.47M	N/A	0.00	∞	N/A	N/A	-235.33%	-182.35%	N/A

Latest VTL, SLN, EPRX, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	-$0.60	-$0.42	-$0.60	$3.58 million	$0.14 million
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A
3/20/2025	Q4 2024	EPRX Eupraxia Pharmaceuticals	-$0.20	-$0.21	-$0.01	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A
VTL Vital Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	7.03	7.03
EPRX Eupraxia Pharmaceuticals	N/A	4.17	4.17
SLN Silence Therapeutics	N/A	9.31	9.31
VTL Vital Therapies	N/A	6.97	6.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
EPRX Eupraxia Pharmaceuticals	N/A
SLN Silence Therapeutics	98.73%
VTL Vital Therapies	15.52%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
EPRX Eupraxia Pharmaceuticals	N/A
SLN Silence Therapeutics	4.10%
VTL Vital Therapies	33.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	66.86 million	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.85 million	N/A	N/A
SLN Silence Therapeutics	100	29.93 million	N/A	Not Optionable
VTL Vital Therapies	10	42.37 million	N/A	Not Optionable

VTL, SLN, EPRX, and ACRS Headlines

Recent News About These Companies

18,000 vulnerable children could lose ‘vital’ therapy as adoption fund faces axe

March 31, 2025 | msn.com

Veterans Deserve Access To Life-Changing Psychedelics Therapy: A Vital Solution For PTSD And Healing

November 11, 2024 | benzinga.com

Respiratory Therapy program continues to thrive at Vermont State University

November 6, 2024 | vermontbiz.com

Respiratory Therapy program continues to thrive at Vermont State University

November 6, 2024 | vermontbiz.com

Lighthouse Center for Vital Living celebrates new building

October 30, 2024 | duluthnewstribune.com

Alternative Wellness Therapies in the Tahoe Basin

October 11, 2024 | tahoedailytribune.com

Addressing Trauma: A Vital Component in Behavioral Health

October 3, 2024 | ajmc.com

Vital Care Receives Strategic Investment From Berkshire Partners, Leonard Green & Partners, and Linden Capital Partners

August 1, 2024 | tmcnet.com

Veterans lobbied for psychedelic therapy, but it may not be enough to save MDMA drug application

July 26, 2024 | msn.com

Ending Therapy

May 24, 2024 | psychologytoday.com

Medication and Therapy

May 23, 2024 | psychologytoday.com

Vardhman Textiles Ltd.

May 22, 2024 | wsj.com

FDA’s Marks: Global Regulatory Convergence Vital to Cell & Gene Therapy Oversight

May 11, 2024 | biospace.com

Vital Spa celebrates a year on Bridge Street

April 28, 2024 | yahoo.com

Guest opinion: Psychedelics as a vital path to healing for veterans

April 28, 2024 | heraldextra.com

Don’t Forget About Vital Signs in Psychiatry Visits

March 12, 2024 | psychologytoday.com

What is therapeutic recreation? Champaign counselors train to include it in their sessions

March 8, 2024 | yahoo.com

Teen Therapy and Psychiatry Online: Hit or Miss?

March 3, 2024 | medpagetoday.com

Vital Ltd VTL

March 2, 2024 | morningstar.com

The Benefits of Teen Outpatient Programs for Behavioral Health

March 2, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTL, SLN, EPRX, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.45 -0.01 (-0.68%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.46 +0.01 (+0.69%)

As of 05/30/2025 07:19 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$3.93 0.00 (0.00%)

Closing price 05/30/2025 03:59 PM Eastern

Extended Trading

$3.89 -0.04 (-1.02%)

As of 05/30/2025 05:26 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Silence Therapeutics NASDAQ:SLN

$5.90 -0.04 (-0.67%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$5.81 -0.09 (-1.53%)

As of 05/30/2025 06:51 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Vital Therapies NASDAQ:VTL

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time